Several polymorphisms, such as rs2295080, rs11121704, and rs12139042, have been shown to be significantly associated with lung and esophageal cancer [58-60], but more attention should be given to the association of mTOR polymorphisms with treatment response to inhibitors of the mTOR pathway. The gene discussed is MTOR; the disease is esophageal cancer.